Editas Medicine Q3 EPS Estimate Increased by Zacks Research

Key Points

• Zacks Research has revised its Q3 2025 earnings per share estimate for Editas Medicine to ($0.41), an improvement from the previous estimate of ($0.42).
• Editas Medicine reported a Q2 loss of ($0.63) per share, missing analyst expectations, while revenues were significantly higher than anticipated at $3.58 million.
• Multiple analysts have adjusted their ratings for Editas Medicine, with HC Wainwright upgrading it to a "buy" rating and raising the target price to $5.00.

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Analysts at Zacks Research boosted their Q3 2025 EPS estimates for Editas Medicine in a note issued to investors on Tuesday, September 2nd. Zacks Research analyst Team now anticipates that the company will post earnings per share of ($0.41) for the quarter, up from their previous forecast of ($0.42). The consensus estimate for Editas Medicine's current full-year earnings is ($2.71) per share. Zacks Research also issued estimates for Editas Medicine's Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.71) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.43) EPS, FY2026 earnings at ($1.55) EPS, Q1 2027 earnings at ($0.46) EPS and Q2 2027 earnings at ($0.46) EPS.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.22). The firm had revenue of $3.58 million during the quarter, compared to analysts' expectations of $1.81 million. Editas Medicine had a negative return on equity of 200.25% and a negative net margin of 608.88%.

Other research analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Editas Medicine from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Wells Fargo & Company raised their price target on shares of Editas Medicine from $3.00 to $4.00 and gave the stock an "equal weight" rating in a report on Wednesday, September 3rd. Robert W. Baird raised their price target on shares of Editas Medicine from $4.00 to $6.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. Finally, HC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Editas Medicine in a report on Friday, September 5th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Editas Medicine currently has an average rating of "Hold" and a consensus price target of $5.10.

Editas Medicine Stock Down 1.3%

Shares of Editas Medicine stock traded down $0.04 during trading on Friday, hitting $2.73. The stock had a trading volume of 864,019 shares, compared to its average volume of 2,794,711. The stock has a 50 day simple moving average of $2.73 and a 200 day simple moving average of $2.00. The company has a market capitalization of $245.03 million, a PE ratio of -0.96 and a beta of 2.16. Editas Medicine has a 1 year low of $0.91 and a 1 year high of $4.12.

Hedge Funds Weigh In On Editas Medicine

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EDIT. Raymond James Financial Inc. bought a new position in Editas Medicine during the fourth quarter valued at approximately $303,000. Ameriprise Financial Inc. raised its position in Editas Medicine by 282.7% during the fourth quarter. Ameriprise Financial Inc. now owns 227,609 shares of the company's stock valued at $289,000 after acquiring an additional 168,134 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Editas Medicine by 162.9% during the fourth quarter. BNP Paribas Financial Markets now owns 144,060 shares of the company's stock valued at $183,000 after purchasing an additional 89,273 shares during the last quarter. Balyasny Asset Management L.P. grew its holdings in Editas Medicine by 647.3% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,300,604 shares of the company's stock valued at $1,652,000 after purchasing an additional 1,126,569 shares during the last quarter. Finally, Bridgeway Capital Management LLC acquired a new position in Editas Medicine during the fourth quarter valued at approximately $190,000. Institutional investors own 71.90% of the company's stock.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.